A study of over 44 million births links preexisting diabetes and congenital heart defects to a 48% higher relative risk. Explore the findings and implications.
Read More »Can Home-Delivered Meals Lower A1C and Blood Pressure? Early Results Offer Clues
Discover how medically tailored meals for diabetes may help lower A1C, improve blood pressure, and support healthier eating, according to early research.
Read More »Below 120 or Below 140? A Major Diabetes Trial Puts Blood Pressure Targets to the Test
Does lowering blood pressure below 120 help people with diabetes? Explore OPTIMAL-DIABETES findings on heart outcomes, kidney risks, and treatment goals.
Read More »The SGLT2 Hemoglobin Effect: A Clue to Cardiorenal Protection?
Learn how SGLT2 inhibitors affect hemoglobin and hematocrit, and what a JAMA meta-analysis reveals about possible heart and kidney benefits.
Read More »Lose 5% Now, Benefit Decades Later? Prediabetes Data Point to a Possible Legacy Effect
A 34-year study links early weight loss in prediabetes to lower cardiovascular risks. Explore the findings and what they mean for prevention.
Read More »Type 1 Diabetes Care Just Changed: The 2026 ADA/EASD Update Clinicians Need to Know
The type 1 diabetes consensus 2026 expands guidance on AID, cardiovascular risk, obesity, complications, psychosocial care, and new therapies.
Read More »Fiber’s Unexpected Bonus: Diabetes Data Show BP Benefit
New trial data suggest dietary fiber supplementation may lower systolic blood pressure in adults with type 2 diabetes and hypertension.
Read More »Low Potassium, Higher Diabetes Risk? A Surprising Clue From Heart Failure Research
Low potassium is usually viewed through a cardiovascular lens, especially in patients with heart failure. However, emerging evidence suggests clinicians may have another reason to pay attention. New research examining the relationship between hypokalemia and diabetes risk found that lower serum potassium levels were associated with a greater risk of …
Read More »SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?
SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …
Read More »Could a Simple Blood Test Predict a Heart Event in Type 2 Diabetes?
Could a routine blood sample someday reveal cardiovascular danger that cholesterol, blood pressure, and HbA1c do not fully capture? New research suggests that epigenetic cardiovascular risk prediction could offer a new way to identify people with type 2 diabetes who face a higher short-term risk of major cardiovascular events. Instead …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.